Abstract
The role of dopamine in sleep-wake regulation is considered as a wakefulness-promoting agent. For the clinical treatment of excessive daytime sleepiness, drugs have been commonly used to increase dopamine release. However, sleep disorders or lack of sleep are related to several dopaminerelated disorders. The effects of dopaminergic agents, nevertheless, are mediated by two families of dopamine receptors, D1 and D2-like receptors; the first family increases adenylyl cyclase activity and the second inhibits adenylyl cyclase. For this reason, the dopaminergic agonist effects on sleep-wake cycle are complex. Here, we review the state-of-the-art and discuss the different effects of dopaminergic agonists in sleep-wake states, and propose that these receptors account for the affinity, although not the specificity, of several effects on the sleep-wake cycle.
Keywords: Dopamine, dopamine agonist, sleep-wake states, wakefulness-promoting agents, receptors, nuclei.
CNS & Neurological Disorders - Drug Targets
Title:Dopaminergic Modulation of Sleep-Wake States
Volume: 16 Issue: 4
Author(s): Andrea Herrera-Solis, Wendy Herrera-Morales, Luis Nunez-Jaramillo and Oscar Arias-Carrion*
Affiliation:
- Unidad de Trastornos del Movimiento y Sueño (TMS). Hospital General Dr. Manuel Gea González, Avenida Calzada de Tlalpan 4800, Tlalpan, Sección XVI, Ciudad de México, C.P. 14080,Mexico
Keywords: Dopamine, dopamine agonist, sleep-wake states, wakefulness-promoting agents, receptors, nuclei.
Abstract: The role of dopamine in sleep-wake regulation is considered as a wakefulness-promoting agent. For the clinical treatment of excessive daytime sleepiness, drugs have been commonly used to increase dopamine release. However, sleep disorders or lack of sleep are related to several dopaminerelated disorders. The effects of dopaminergic agents, nevertheless, are mediated by two families of dopamine receptors, D1 and D2-like receptors; the first family increases adenylyl cyclase activity and the second inhibits adenylyl cyclase. For this reason, the dopaminergic agonist effects on sleep-wake cycle are complex. Here, we review the state-of-the-art and discuss the different effects of dopaminergic agonists in sleep-wake states, and propose that these receptors account for the affinity, although not the specificity, of several effects on the sleep-wake cycle.
Export Options
About this article
Cite this article as:
Herrera-Solis Andrea, Herrera-Morales Wendy , Nunez-Jaramillo Luis and Arias-Carrion Oscar *, Dopaminergic Modulation of Sleep-Wake States, CNS & Neurological Disorders - Drug Targets 2017; 16 (4) . https://dx.doi.org/10.2174/1871527316666170320145429
DOI https://dx.doi.org/10.2174/1871527316666170320145429 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biological Relevance of Lysophospholipids and Green Solutions for Their Synthesis
Current Organic Chemistry Dietary Intake and Bone Status with Aging
Current Pharmaceutical Design Orally Administrated Small Molecule Drugs with Intestine Targeted Profile: Recent Development and Prospects
Current Medicinal Chemistry Diabetes, Cognitive Function, and the Blood-Brain Barrier
Current Pharmaceutical Design Effective Biomarkers for Proof-of-Concept
Current Medical Imaging Delivery of Curcumin and Medicinal Effects of the Copper(II)-Curcumin Complexes
Current Pharmaceutical Design Synthesis of 8,10-disubstituted-triazoloperimidines from (E)-3-(dimethylamino)-1-(8- phenyl-8H-[1,2,4]triazolo[4,3-a]perimidin-10-yl)prop-2-en-1-one and Their Antimicrobial Activity
Current Organic Synthesis Advances in Stem Cell Therapy for Brain Diseases via the Intranasal Route
Current Pharmaceutical Biotechnology Chronic Effects of Cocaine on Dopaminergic and Serotonergic Systems of Rats
Current Molecular Imaging (Discontinued) The Yin and Yang of CD4+ Regulatory T Cells in Autoimmunity and Cancer
Current Medicinal Chemistry Modulating the Amyloidogenesis of α-Synuclein
Current Neuropharmacology Diabetic Cardiomyopathy: Electromechanical Cellular Alterations
Current Vascular Pharmacology Co-Morbid Erectile Dysfunction (ED) and Antidepressant Treatment in a Patient – A Management Challenge?
Current Drug Targets TRPV1: On the Road to Pain Relief
Current Molecular Pharmacology Electrochemistry of Alzheimer Disease Amyloid Beta Peptides
Current Medicinal Chemistry An Insight on the Association of Psychological Studies, Cognitive Sciences and Meditation in Treating Depression
Current Psychopharmacology Preface:
Central Nervous System Agents in Medicinal Chemistry Common Environmental Factors May Underpin the Comorbidity Between Generalized Anxiety Disorder and Mood Disorders Via Activated Nitrooxidative Pathways
Current Topics in Medicinal Chemistry Advances in Ocular Iontophoresis Research
Recent Patents on Nanomedicine ERRATUM
Current Neuropharmacology